WuXi Biologics controversies

U.S. national-security and military-civil-fusion allegations

U.S. lawmakers introduced legislation that could restrict federal contracts with WuXi Biologics and other biotechnology companies amid national-security concerns. The criticism included allegations that WuXi Biologics had worked closely with the People's Liberation Army as part of China's military-civil fusion strategy. The company denied the allegations. The controversy led to calls by members of a U.S. House select committee for sanctions and contributed to market pressure on the company.